New drug cocktail shows promise for tough blood cancer
NCT ID NCT05861050
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study is testing a combination of three drugs (glofitamab, venetoclax, and lenalidomide) in people newly diagnosed with a fast-growing type of mantle cell lymphoma. The goal is to see if this mix is safe and works better than current treatments. About 50 adults aged 18 to 80 with high-risk disease will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLASTOID VARIANT MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mount Sinai School of Medicine
RECRUITINGNew York, New York, 10029, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?
- Smartwatches track hidden heart risk in blood cancer patients
- Triple-Drug attack aims to outsmart mantle cell lymphoma
- Double-Pronged immune cells take aim at stubborn blood cancers
- New drug combo aims to outsmart Hard-to-Treat lymphoma